| ［1］ |
Yang K, Oak A, Elewski BE. Use of IL⁃23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review［J］. Am J Clin Dermatol, 2021,22（2）:173⁃192. doi: 10.1007/s40257⁃020⁃00578⁃0.
|
| ［2］ |
Menter A, Krueger GG, Paek SY, et al. Interleukin⁃17 and interleukin⁃23: a narrative review of mechanisms of action in psoriasis and associated comorbidities［J］. Dermatol Ther （Heidelb）, 2021,11（2）:385⁃400. doi: 10.1007/s13555⁃021⁃00483⁃2.
|
| ［3］ |
Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model［J］. J Invest Dermatol, 2015,135（2）:445⁃453. doi: 10.1038/jid. 2014.426.
|
| ［4］ |
Steel K, Srenathan U, Ridley M, et al. Polyfunctional, proinflammatory, tissue⁃resident memory phenotype and function of synovial interleukin⁃17A+CD8+ T cells in psoriatic arthritis［J］. Arthritis Rheumatol, 2020,72（3）:435⁃447. doi: 10. 1002/art.41156.
|
| ［5］ |
Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL⁃23 signaling in psoriatic arthritis: a molecular insight［J］. Clin Immunol, 2019,206:15⁃22. doi: 10. 1016/j.clim.2018.09.002.
|
| ［6］ |
Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti⁃IL⁃12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non⁃biological and biological anti⁃tumour necrosis factor therapy: 6⁃month and 1⁃year results of the phase 3, multicentre, double⁃blind, placebo⁃controlled, randomised PSUMMIT 2 trial［J］. Ann Rheum Dis, 2014,73（6）:990⁃999. doi: 10.1136/annrheumdis⁃2013⁃204655.
|
| ［7］ |
Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020, 395（10230）:1115⁃1125. doi: 10.1016/s0140⁃6736（20）30265⁃8.
|
| ［8］ |
Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020, 395（10230）:1126⁃1136. doi: 10.1016/s0140⁃6736（20）30263⁃4.
|
| ［9］ |
Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis［J］. Rheumatology （Oxford）, 2020,59（Suppl 1）:i37⁃37i46. doi: 10.1093/rheumatology/kez383.
|
| ［10］ |
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology［J］. J Am Acad Dermatol, 2017,76（3）:377⁃390. doi: 10.1016/j.jaad.2016.07.064.
|
| ［11］ |
Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events［J］. J Am Acad Dermatol, 2017,77（4）:650⁃656.e3. doi: 10.1016/j.jaad.2017.06.028.
|
| ［12］ |
Egeberg A, Gisondi P, Carrascosa JM, et al. The role of the interleukin⁃23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1695⁃1706. doi: 10.1111/jdv.16273.
|
| ［13］ |
Li Y, Golden JB, Camhi MI, et al. Protection from psoriasis⁃related thrombosis after inhibition of IL⁃23 or IL⁃17A［J］. J Invest Dermatol, 2018,138（2）:310⁃315. doi: 10.1016/j.jid.2017. 09.021.
|
| ［14］ |
Fatkhullina AR, Peshkova IO, Dzutsev A, et al. An interleukin⁃23⁃interleukin⁃22 axis regulates intestinal microbial homeostasis to protect from diet⁃induced atherosclerosis［J］. Immunity, 2018,49（5）:943⁃957.e9. doi: 10.1016/j.immuni.2018.09.011.
|
| ［15］ |
Lutgens E, Joffre J, van Os B, et al. Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies［J］. Atherosclerosis, 2021,335:98⁃109. doi: 10.1016/j.atherosclerosis.2021.09.024.
|
| ［16］ |
Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double⁃blind, placebo⁃controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis （the VIP⁃U Trial）［J］. J Invest Dermatol, 2020,140（1）:85⁃93.e2. doi: 10. 1016/j.jid.2019.07.679.
|
| ［17］ |
Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry （PSOLAR）［J］. J Drugs Dermatol, 2015,14（7）:706⁃714.
|
| ［18］ |
Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
|
| ［19］ |
Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. doi: 10.1111/jdv.15653.
|
| ［20］ |
Poizeau F, Nowak E, Kerbrat S, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti⁃interleukin 12/23p40 antibody ustekinumab［J］. JAMA Dermatol, 2020,156（11）:1208⁃1215. doi: 10.1001/jamadermatol. 2020.2977.
|
| ［21］ |
Carvalho AV, Romiti R, Souza CD, et al. Psoriasis comorbidities: complications and benefits of immunobiological treatment［J］. An Bras Dermatol, 2016,91（6）:781⁃789. doi: 10.1590/abd1806⁃4841.20165080.
|
| ［22］ |
Teklu M, Zhou W, Kapoor P, et al. Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: an observational cohort study［J］. J Am Acad Dermatol, 2021,84（5）:1329⁃1338. doi: 10.1016/j.jaad.2020.12.044.
|
| ［23］ |
Pirowska M, Obtułowicz A, Lipko⁃Godlewska S, et al. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis［J］. Postepy Dermatol Alergol, 2018,35（4）:360⁃366. doi: 10.5114/ada.2018.77665.
|
| ［24］ |
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity［J］. Expert Opin Pharmacother, 2019,20（7）:863⁃872. doi: 10.1080/14656566.2019.1583207.
|
| ［25］ |
Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials （ReSURFACE 1 and ReSURFACE 2）［J］. J Drugs Dermatol, 2020,19（8）:703⁃708. doi: 10.36849/JDD.2020.5337.
|
| ［26］ |
Ruiz⁃Villaverde R, Ayén⁃Rodriguez A, Llamas⁃Molina JM, et al. Risankizumab as a promising therapeutic approach in obese patients［J］. Dermatol Ther, 2020,33（3）:e13323. doi: 10.1111/dth.13323.
|
| ［27］ |
Alinaghi F, Tekin HG, Burisch J, et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease⁃a systematic review and meta⁃analysis［J］. J Crohns Colitis, 2020,14（3）:351⁃360. doi: 10.1093/ecco⁃jcc/jjz152.
|
| ［28］ |
Noviello D, Mager R, Roda G, et al. The IL23⁃IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges［J］. Front Immunol, 2021,12:611256. doi: 10.3389/fimmu.2021.611256.
|
| ［29］ |
Moschen AR, Tilg H, Raine T. IL⁃12, IL⁃23 and IL⁃17 in IBD: immunobiology and therapeutic targeting［J］. Nat Rev Gastroenterol Hepatol, 2019,16（3）:185⁃196. doi: 10.1038/s41575⁃018⁃0084⁃8.
|
| ［30］ |
Pugliese D, Daperno M, Fiorino G, et al. Real⁃life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG⁃IBD study［J］. Dig Liver Dis, 2019,51（7）:972⁃977. doi: 10.1016/j.dld.2019. 03.007.
|
| ［31］ |
Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2018,78（2）:383⁃394. doi: 10.1016/j.jaad.2017. 06.043.
|
| ［32］ |
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis （BE VIVID）: efficacy and safety from a 52⁃week, multicentre, double⁃blind, active comparator and placebo controlled phase 3 trial［J］. Lancet, 2021,397（10273）:487⁃498. doi: 10.1016/S0140⁃6736（21）00125⁃2.
|
| ［33］ |
Trafford AM, Parisi R, Kontopantelis E, et al. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（12）:1390⁃1403. doi: 10.1001/jamadermatol.2019.3056.
|
| ［34］ |
Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（4）:421⁃429. doi: 10.1001/jamadermatol. 2020.0024.
|
| ［35］ |
Ergen EN, Yusuf N. Inhibition of interleukin⁃12 and/or interleukin⁃23 for the treatment of psoriasis: what is the evidence for an effect on malignancy?［J］. Exp Dermatol, 2018,27（7）:737⁃747. doi: 10.1111/exd.13676.
|
| ［36］ |
Thatiparthi A, Martin A, Liu J, et al. Biologic treatment algorithms for moderate⁃to⁃severe psoriasis with comorbid conditions and special populations: a review［J］. Am J Clin Dermatol, 2021,22（4）:425⁃442. doi: 10.1007/s40257⁃021⁃00603⁃w.
|
| ［37］ |
Gang W, Gu H, Zheng M, et al. Experts opinion on the use of biologic agents in psoriatic patients during COVID⁃19 outbreak［J］. Int J Dermatol Venereol, 2020,3（2）:68⁃69. doi: 10.1097/JD9.0000000000000097.
|
